

Lupus: Benlysta

	mber Information				
1.	Last Name:	2. First Name: 5. Ge			
3.	Trillium ID #:	4. Date of Birth:		5. Gender:	
Pres	scriber Information				
1.	Prescriber Name:	2. NPI #:			
4.	Mailing Address:	ffice Staff):	City:	State: Zip:	
5.	Phone #:	Ext	Fax #:		
	g Information				
1.	Drug Name: Benlysta	2. Strength:	3. Qu	antity Per 30 Days:	
		☐ up to 30 Days ☐ 60 Days ☐			
Clin	ical Information				
Ini	tial authorization (answer c	uestions 1-7)			
	· ·	•	vthematosus (SLF)?] Yes □ No	
 Does the member have a diagnosis of active systemic lupus erythematosus (SLE)? ☐ Yes ☐ No Does the member have a diagnosis of Lupus Nephritis? ☐ Yes ☐ No 					
		, ,		s □ No	
 3. Is the medication being prescribed by or in consultation with a rheumatologist? ☐ Yes ☐ No 4. Is the member auto-antibody positive? ☐ Yes ☐ No 					
	•	, ,		(110.115)	
5. Is the member utilizing the medicine in combination with standard treatment regimens (NSAIDs, corticosteroids, anti-malarial, or immunosuppressive drugs) or standard treatment regimens were not tolerated					
		• • • • • • • • • • • • • • • • • • • •	standard treatment re	gimens were not tolerated	
_					
6.	6. Does the member have a diagnosis of severe active lupus nephritis or severe active central nervous				
	•				
7.	Is the medication being used	d concurrently with other biologics a	and/or IV cyclophospha	amide? □ Yes □ No	
Fo	r re-authorization (answer	question 8)			
8.	or beneficial? □ Yes □ No 6. Does the member have a diagnosis of severe active lupus nephritis or severe active central nervous system lupus? □ Yes □ No 7. Is the medication being used concurrently with other biologics and/or IV cyclophosphamide? □ Yes □ No For re-authorization (answer question 8) 8. Is there documented improvement in functional impairment such as fewer flares that required steroid treatment, lower average daily oral prednisone dose, improved daily function either as measured through a validated				
	lower average daily oral pre-	there documented improvement in functional impairment such as fewer flares that required steroid treatment,			
	functional scale or through improved daily performance documented at clinic visits, or sustained improvement in				
	laboratory measures of lupu	ıs activity? □ Yes □ No			
	Please attach current pro	ogress notes documenting disea	se status and clinica	I response to the medicine.	
Si	gnature of Prescriber:		Date:		

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Trillium – Lupus - Benlysta Orig. 7/2024